Bio-Connect
The figure shows a typical standard curve for the bioactive human Sclerostin ELISA. The immunoassay is calibrated against recombinant human bioactive Sclerostin.
The figure shows a typical standard curve for the bioactive human Sclerostin ELISA. The immunoassay is calibrated against recombinant human bioactive Sclerostin.
The figure shows a typical standard curve for the bioactive human Sclerostin ELISA. The immunoassay is calibrated against recombinant human bioactive Sclerostin.

Human bioactive Sclerostin ELISA

Research Use Only
BI-20472
Biomedica
Assay Sample TypeSerum, EDTA plasma and citrate plasma
Product group Assays
€ 689,00
96 tests
Sign in to order and to see your custom pricing.
Large volume orders?
Order with a bulk request

Overview

  • Supplier
    Biomedica
  • Product Name
    Human bioactive Sclerostin ELISA
  • Delivery Days Customer
    7
  • Assay Detection Range
    0 – 320 pmol/l (= 0 – 7 200 pg/ml)
  • Assay Precision
    In-between-run (n=7): ≤5 % CV. Within-run (n=3): ≤ 1 % CV
  • Assay Sample Type
    Serum, EDTA plasma and citrate plasma
  • Assay Sensitivity
    1.9 pmol/l (= 42.7 pg/ml)
  • Assay Specificity
    Endogenous and recombinant bioactive Sclerostin.
  • Assay Test Principle
    The Biomedica Sclerostin ELISA is a sandwich enzyme immunoassay for the quantitative determination of bioactive Sclerostin (SOST) in human serum and plasma samples.
  • Assay Time
    2 h / 1 h / 30 min
  • Certification
    Research Use Only
  • Scientific Description
    The bioactive Sclerostin ELISA kit is a 3.5 hour, 96-well sandwich ELISA for the quantitative determination of bioactive Sclerostin in human serum, EDTA-plasma, and citrate plasma. The human Sclerostin ELISA kit employs human serum-based standards to ensure the measurement of biologically reliable data. The bioactive Sclerostin ELISA kit uses highly purified, epitope mapped antibodies with characterized binding kinetics.
  • UNSPSC
    41116133

References

  • Pereira L, Mendonça L, Magalhães J, et al. Vascular calcification in peritoneal dialysis patients and its association with bone-derived molecules and bone histomorphometry. Nefrologia (Engl Ed). 2024;44(2):224-232.
    Read more